

Meeting Increased Pressures to Detect and Quantify Host Cell Proteins in Biotherapeutics by LC/MS

Sean M McCarthy, PhD

1

Introduction – Importance of HCPs

- Residual host cell proteins (HCPs) from recombinant production are classified as process-related impurities.
 - HCPs can elicit an unpredictable immune response in patients.
 - Need to be monitored as part of regulatory guidelines
- European regulations in effect since 1997:
 - `6.2 Validation of the purification procedure The ability of the purification process to remove other specific contaminants such as <u>host-</u> <u>cell proteins</u> ... should also be demonstrated'
- Current analytical methods (typically ELISA, gels, blots) are:
 - expensive,
 - subjective,
 - time-consuming to develop,
 - Require prior knowledge about the contaminant proteins
- Composition of HCPs is extremely heterogeneous and changes with production and purification procedures.

Business Impacts of HCP Issues



- During the development of Omnitrope, an immunogenicity issue emerged with an early version of the product.
- Up to 60% of patients enrolled in two clinical studies developed anti-hGH antibodies, and 100% developed anti-HCP antibodies.
- The cause was excess host cell protein levels, which was resolved by the manufacturer with purification process changes.


What is the cost of halting clinical trials or losing drug efficacy over time?



Today's approach to HCP's: 12 months to develop a product-specific quantitative immunoassay



Immunoassays are sensitive but inflexible




- Process Changes may require new assay development.
- Hurdle to Biosimilar approval
- Regulators not all that happy with this current technology.



Biopharm International, Volume 13, Number 6, pp. 38-45, May 2000

Antibody Expression

THE SCIENCE OF WHAT'S POSSIBLE.™




- Chimeric anti-phosphotyrosine IgG1 mAb (PTG1) expressed in 2 cell lines (CHO-S and DG44)
- Purified by Protein A chromatography (two different protocols).
- Two cell lines (DG44 and CHO-S) containing no PTG1 vector were also grown under the same conditions and purified on a Protein A column.
- Five proteins were spiked in PTG1
 - 4,000 fmoles LA (bovine beta-lactoglobulin), 800 fmoles PHO (rabbit glycogen phosphorylase b), 320 fmoles ADH (yeast alcohol dehydrogenase), 80 fmoles BSA (bovine serum albumin), and 16 fmoles ENL (yeast enolase).
- Samples analysed by LC/ MS^E

"Catalog" Host Cell Proteins (HCP's) early in downstream processing

THE SCIENCE OF WHAT'S POSSIBLE.™


Waters



©2011 Waters Corporation


Cataloging HCP's in a biotherapeutic protein sample

Waters



MS^E: An Alternate Scanning Methodology for Acquiring Peptide and Fragmentation Data

THE SCIENCE OF WHAT'S POSSIBLE.™



Silva J.C. et al (2005) Quantitative Proteomic Analysis by Accurate Mass Retention Time Pairs Analytical Chemistry 77(7): 2187-2200.


LC Conditions for HCP discovery

nanoACQUITY[™] UPLC[®] system with 2D technology

•First Dimension (1D) pH=10: High Loading Capacity, high pH resistance (XBridge)

•Online dilution (1:10) of the eluent from 1D before analyte trapping onto the 2D column.

- •Trap column: 5-µm Symmetry for high carbon loading facilitates peptide retention
- •Second Dimension (2D) pH=2.4: analytical chromatography of each fraction in turn with longer gradient to maximize resolution for each fraction.
- •Digital Fraction 'Merge': digitally group peptides that fall into different fractions by treating the dataset as if it were a <u>1D LC</u> run.






VVaters

Reproducibility of 2D Chromatography: T43 ENL (VNQIGTLSESIK), 24 fmoles on column, Fraction 3/5 90 min gradients

THE SCIENCE OF WHAT'S POSSIBLE.™



©2011 Waters Corporation

Absolute Protein Quantitation (Hi3) by LC-MS^E

THE SCIENCE OF WHAT'S POSSIBLE."

To date a majority of the guar

ling of the und

lied through direct and in

iology guiding the response to an applied perturbation. G

ample would enable dat

Absolute Quantification of Proteins by LCMS^E A VIRTUE OF PARALLEL MS ACQUISITION

Jeffrey C. Silva‡§, Marc V. Gorenstein‡, Guo-Zhong Li‡, Johannes P. C. Vissers¶, and Scott J. Geromanost


ethods have dominated the In their mitrorial marked in the down state of the instance of the distribution between the state of the distribution of the distribution between the state of the distribution of the distribution between the state of the distribution of the distribution between the state of the distribution of the distr distribution of the d ion: the average MS signal response for nee tryptic peptides per mole of protein a coefficient of variation of less than nse factor. The teins tested in this study. A lous proteins of varying conhe absolute quantity of the standard pro-mined with a relative error of less than rage MS signal responses of the three sptides from each protein were plotted collated protein concentrations, and this a linear relationship with an R^o value of the peak area of identical peptides bet ity of these m is valuable for the underst

rough identification of proteins, discovering ers, studying protein involvement in specific difying protein targets in drug technique that is used in these

thusetts 01757-1322 CE Almere

40000 35000 30000 250000 20000 ď 150000 Sign 100000 5000 2000 4000 6000 8000 10000 12000 14000 Concentration (fmoles on column)

Basis: Intensity of Top 3 Peptides of each Protein



Molecular & Cellular Proteomics 5:144–156, 2006.

Example: Comparing HCPs in a therapeutic mAbisolated by two Protein A purification methods


THE SCIENCE OF WHAT'S POSSIBLE.™

ers

	Protein ID and spe	Protocol A (ppm or ng/mg)	Protocol B (ppm or ng/mg)	
	40S ribosomal protein S3 (mouse)	663	561
	100 site as a set a la set a la 64 /	-T,	216	83
Post-Protein A Purification Step	Method A	Method B	580	1265
r ost r oten Ar anneadon otep			2416	1844
				690
		73	2467	1899
No. proteins identified	49		82 51	87
				219 3204
		2.7x	1256 89	451
	4.0		3428	2386
HCP Levels	1.0x		530	652
			7393	325
		3.5x	468	448
			199	754
Total HCP by ELISA Assay (ppm) 1.0x		1,200	1480
			764	731
	Lysosomal alpha glucosidase	1607	541	
Determine:	Nucleolin (hamster	1068	14191	
	Peroxiredoxin 1 (mous	122	229	
✓ Total HCP Level	Procollagen C endopeptidase enhancer (mouse)		89	2995
	Pyruvate kinase isozyme (510	1624	
✓ HCP Complexity	S methyl 5 thioadenosine phospho	34 553	70 705	
✓ Which Proteins?	Serine protease HTRA1 (mouse) Serum albumin precursor (bovine) - 80 fmoles IS		100	123
	T complex protein subunits (mouse)		6060	777
✓ At what Levels?	Transcription factor HES 5	104	293	
	Tubulin alpha and beta chain (mouse)		1839	10072

Monitor Host Cell Proteins (HCP's) later in downstream processing using MRM

Waters THE SCIENCE OF WHAT'S POSSIBLE.™



MRM Monitoring of HCP's

Concentration (ppm or ng/mg)

DG44 cells CHO-S cells

4.25

5.71

- Verify facilitates development of MRM methods for multiple HCP's via "signature" peptides
- Absolute quantification can be performed by using stable isotopically labeled peptide standards
- Assay extremely simple to update/ change



Protein ID

and species

78 kDa glucose regulated protein (hamster)

Actin isoforms (hamster)

Alcohol dehydrogenase (yeast) - 560 ppm (ADH) Clusterin (mouse)

Cofilin 1 (mouse)

Elongation factor 1 and 2 (hamster) Enolase (yeast) - 13 ppm (ENL)

Glyceraldehyde 3 phosphate dehydrogenase (hamster)

Glycogen phosphorylase (rabbit) - 530 ppm (PHC

Heat shock 70 kDa protein (mouse)

Heat shock cognate 71 kDa protein (mouse)

Heat shock protein HSP 90 alpha(mouse)

alpha lactalbumin (bovine) - 1,200 ppm (LA)

Lipoprotein lipase (hamster)

Lysosomal alpha glucosidase (mouse)

Nucleolin (hamster

Pyruvate kinase isozyme (mouse)


Serine protease HTRA1 (mouse)


Serum albumin precursor (bovine) - 100 ppm (BSA)

T complex protein subunits (mouse)

ID

no





THE SCIENCE OF WHAT'S POSSIBLE.™

Development of an HCP MRM Assay

THE SCIENCE OF WHAT'S POSSIBLE.™

 Discovery Phase (QTof)

 Identify HCPs using LCMS^E

 MS^E Fragmentation

Monitoring Phase (QQQ)

- Select 3-5 peptides per protein (best ionizing, good fragmentation)
 - Produce recombinant HCP?
- Produce synthetic peptides
- Identify best 2-3 MRM transitions per peptide (Infusion Experiment)
 - Optimize Cone Voltage
 - Optimize Collision Energy
- LC/MS method development
 - Spike peptides into biotherapeutic digest to identify product interferences
 - (Optional) Stable isotope labeled peptide for absolute quantitation
 - Investigate the linearity of the MRM assay


QQQ MRM method to monitor Top 20 HCP Proteins (2) Peptides, 58 Transitions) from method 1




	X						
😰 SIR 🛛 📝	MRM 📝 MS S	Scan 📝 Parents	📝 Daughters	🖉 Neutral Loss	Survey	📝 ScanWave MS	🖉 ScanWave DS
Points Per Peak: 8.333							
Total Run Time: 20.00 🖶				<u> </u>	10 I	20m	
No. Type Information						Time	
8 Image: Marked ma	mass pairs, Time 0. mass pairs, Time 0. mass pairs, Time 8. mass pairs, Time 8. mass pairs, Time 8. mass pairs, Time 9. mass pairs, Time 9. mass pairs, Time 9. mass pairs, Time 10. mass pairs, Time 10. mass pairs, Time 10.	00 to 9.00, ES+ (Nucli 00 to 9.00, ES+ (Elon; 00 to 9.00, ES+ (78 Vi 00 to 10.00, ES+ (78 Vi 00 to 10.00, ES+ (Pri 00 to 10.00, ES+ (9i) 00 to 10.00, ES+ (400; 00 to 11.00, ES+ (Nai) 00 to 11.00, ES+ (Nai) 0.00 to 12.00, ES+ (Co 0.00 to 12.00, ES+ (Hei 0.00 to 12.00, ES	gation STTTGHLIYK EIIANDQGNR) Iothelial INEKPQVIA Jvate APIIAVTR) Seraldehyde GAAQN ELAEDGYSGVEVR Ielolin SVSLYYTGEI Ingation ALIAAQYSG, scent IEDLSQQAQL Scent IEDLSQQAQL Stddyl IEVEKPFAIAK Id YGQISEVVVK)) DYESGR) IIIPASTGAAK)) () AQVR) AAAEK) E) GLSPDTPEEK)			

HCP T44 Peptide MS^E fragmentation

Waters THE SCIENCE OF WHAT'S POSSIBLE.™



MRM Interference for a HCP Peptide MRM Transition




ers


THE SCIENCE OF WHAT'S POSSIBLE.™

Hi3 vs. MRM quantitation data for a 58 kD HCP demonstrates common results





Analytical Reproducibility for 29 HCP Proteins (58 MRM Transitions)



THE SCIENCE OF WHAT'S POSSIBLE.™

More Flexibility for HCP Analysis

- Waters THE SCIENCE OF WHAT'S POSSIBLE.[™]
- Using the same technologies you use for protein characterization you can also identify HCP's in your product.
 - 2DLC/MS^E and the most accurate bioinformatics platform are all required to produce sensitive high quality results
 - Catalog (Identify and quantitate) and compare HCP's in early stages of processing.
- Easily developed MRM assays can monitor low ppm level HCP's in later processing steps and in the purified drug.
 - These MRM assays are readily modified to facilitate faster process development/improvement cycles.
 - Such MRM assays are commonly used today for regulated analyses, and could be readily validated for future QC needs.

Waters THE SCIENCE OF WHAT'S POSSIBLE.